Q-code: Temporary codes Temporary codes
644 codes
Billing context
Q-codes are temporary national codes recognized by Medicare. For drugs they include biosimilar products (Q51xx) and other drugs, biologicals, and skin substitutes that are not yet assigned a permanent code. Units follow the dosage in the descriptor.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| Q9954 | Oral magnetic resonance contrast agent, per 100 ml | — | Apr 1, 2005 | Active |
| Q9955 | Injection, perflexane lipid microspheres, per ml | — | Apr 1, 2005 | Active |
| Q9956 | Injection, octafluoropropane microspheres, per ml | $40.323per 1 ML | Apr 1, 2005 | Active |
| Q9957 | Injection, perflutren lipid microspheres, per ml | $40.323per 1 ML | Apr 1, 2005 | Active |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | $0.080per 1 ML | Jul 1, 2005 | Active |
| Q9959 | High osmolar contrast material, 150-199 mg/ml iodine concentration, per ml | — | Jul 1, 2005 | Active |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml | — | Jul 1, 2005 | Active |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | $0.205per 1 ML | Jul 1, 2005 | Active |
| Q9962 | High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml | — | Jul 1, 2005 | Active |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | $0.219per 1 ML | Jul 1, 2005 | Active |
| Q9964 | High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml | — | Jul 1, 2005 | Active |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | $1.787per 1 ML | Jan 1, 2008 | Active |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | $0.421per 1 ML | Jan 1, 2008 | Active |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | $0.186per 1 ML | Jan 1, 2008 | Active |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | — | Jan 1, 2010 | Active |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | — | Jan 1, 2013 | Ended Dec 31, 2025 |
| Q9970 | Injection, ferric carboxymaltose, 1mg | — | Jul 1, 2014 | Ended Dec 31, 2014 |
| Q9972 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | — | Jul 1, 2014 | Ended Dec 31, 2014 |
| Q9973 | Injection, epoetin beta, 1 microgram, (non-esrd use) | — | Jul 1, 2014 | Ended Dec 31, 2014 |
| Q9974 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | — | Jul 1, 2014 | Ended Dec 31, 2014 |
| Q9975 | Injection, factor viii fc fusion protein (recombinant), per iu | — | Apr 1, 2015 | Ended Dec 31, 2015 |
| Q9976 | Injection, ferric pyrophosphate citrate solution, 0.1 mg of iron | — | Jul 1, 2015 | Ended Dec 31, 2015 |
| Q9977 | Compounded drug, not otherwise classifiedNOC / NOS | — | Jul 1, 2015 | Ended Dec 31, 2015 |
| Q9978 | Netupitant 300 mg and palonosetron 0.5 mg | — | Jul 1, 2015 | Ended Dec 31, 2015 |
| Q9979 | Injection, alemtuzumab, 1 mg | — | Oct 1, 2015 | Ended Dec 31, 2015 |
| Q9980 | Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mg | — | Jan 1, 2016 | Ended Dec 31, 2016 |
| Q9981 | Rolapitant, oral, 1 mg | — | Jul 1, 2016 | Ended Dec 31, 2016 |
| Q9982 | Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries | — | Jul 1, 2016 | Active |
| Q9983 | Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries | — | Jul 1, 2016 | Active |
| Q9984 | Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg | — | Jul 1, 2017 | Ended Dec 31, 2017 |
| Q9985 | Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mgNOC / NOS | — | Jul 1, 2017 | Ended Dec 31, 2017 |
| Q9986 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | — | Jul 1, 2017 | Ended Dec 31, 2017 |
| Q9987 | Pathogen(s) test for platelets | — | Jul 1, 2017 | Ended Dec 31, 2017 |
| Q9988 | Platelets, pheresis, pathogen-reduced, each unit | — | Jul 1, 2017 | Ended Dec 31, 2017 |
| Q9989 | Ustekinumab, for intravenous injection, 1 mg | — | Jul 1, 2017 | Ended Dec 31, 2017 |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | $2,060.132per Less than or equal to 100 MG | Jul 1, 2018 | Active |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | $2,060.132per Greater than 100 MG | Jul 1, 2018 | Active |
| Q9993 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | — | Jul 1, 2018 | Ended Dec 31, 2018 |
| Q9994 | In-line cartridge containing digestive enzyme(s) for enteral feeding, each | — | Jul 1, 2018 | Ended Dec 31, 2018 |
| Q9995 | Injection, emicizumab-kxwh, 0.5 mg | — | Jul 1, 2018 | Ended Dec 31, 2018 |
| Q9996 | Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg | — | Jan 1, 2025 | Active |
| Q9997 | Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg | $8.591per 1 MG | Jan 1, 2025 | Active |
| Q9998 | Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg | $10.480per 1 MG | Jan 1, 2025 | Active |
| Q9999 | Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg | $13.246per 1 MG | Apr 1, 2025 | Active |